FibroBiologics, Inc. has unveiled promising preclinical data on its proprietary thymic organoid platform, which shows potential for reversing age-related immune decline by restoring thymic function. Presented at the Keystone Symposia on Aging and Immunity, this platform leverages a transplantable thymic micro-organoid system developed from selectively screened fibroblasts and thymic stromal cells. The organoids are produced through a rapid, three-day culture process and are designed for clinical scalability, being both cryopreservable and injectable.

The findings underscore the critical role of the thymus in T cell development, which diminishes with age due to thymic involution. This decline contributes to reduced T cell output and impaired immune responses, increasing vulnerability to infections and diseases. In immunodeficient mouse models, the transplanted thymic organoids successfully generated diverse T cell lineages, including alpha-beta (αβ) T cells and natural killer T (NKT) cells, demonstrating a robust T cell receptor repertoire and functional immune responses. Notably, in a targeted cancer model, organoid-derived T cells exhibited anti-tumor activity, slowing tumor growth and enhancing the activation of NK cells, indicating a systemic immune response.

The implications of these findings are significant for the field of aging biology and immunotherapy. The ability to restore thymic function and generate functional, antigen-specific T cells could shift current paradigms in age-related immune interventions and cancer therapies. This platform may accelerate drug development timelines for therapies aimed at enhancing immune resilience in older populations or those recovering from immunosuppressive treatments, positioning FibroBiologics at the forefront of innovative solutions in longevity science.

Source: globenewswire.com